Tag Archives: Teva Pharmaceutical Industries Ltd.

Endo coming out of the darkness into the light; contrarians, buy this name.

The News: Endo International Plc (Dublin IRL) on Tuesday (August 8, 2017) lowered its full-year revenue forecast, saying it expected lower sales of branded drugs to add to the pricing… Read more »

Teva stock crashes on 2Q earnings disaster; run for the hills, or buy at fire sale price?

The News: Teva Pharmaceutical Industries Ltd., which has been without a permanent CEO for six months, plunged $11.74, or 36% last week, to $20.60–the most in almost two decades. The… Read more »

Pernix soars on absolutely no news; naturally, rumors of a takeout flourish

The News: Pernix Therapeutics Holdings Inc. (Nasdaq:PTX) was one of the week’s top gainers, rocketing $2.02, or 50%, to $6.33 Monday (May 8, 2017)–without a press release being issued, or other… Read more »

Cardinal Health does face plant on skanky earnings guidance; even deal for some Medtronic assets raises concerns

The News: Cardinal Health Inc. (Dublin OH) struck a deal to buy part of Medtronic PLC’s (Dublin IRL) patient monitoring and recovery unit for $6.1 billion, bringing businesses under Cardinal’s roof… Read more »

Teva reports 4Q earnings surprise; but 2017 guidance seen “through a glass darkly.”

The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) reported Monday (February 13, 2017) that fourth-quarter sales surged 33% year-over-year to $6.5 billion, topping analysts’ estimates of $6.3 billion. The company… Read more »

Teva’s CEO Vigodman history; sudden departure calls for fearless successor

The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) suddenly found itself without a permanent CEO on Tuesday (February 7, 2017) after Erez Vigodman stepped down, leaving new management to… Read more »

FTC opens antitrust investigation of Mylan’s EpiPen dominance; isn’t it high time we live up to Churchill’s rejoinder?

The News: Mylan on Monday (January 30, 2017) acknowledged that the US Federal Trade Commission asked the company “months ago” to provide information about the allergy therapy EpiPen (epinephrine) as… Read more »

Teva loses four patents on Copaxone; alright, what’s the good news?

The News: A US court invalidated four patents covering Teva Pharmaceutical Industries Ltd.’s (Petach Tikva ISR) three-times weekly version of Copaxone (glatiramer acetate) based on obviousness, following a challenge by… Read more »

Allergan wraps up 2016 M&A with LifeCell buy for $2.9 billion; analysts lavish kudos all around

Dublin-based Allergan said on December 19, 2016 it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP (San Antonio TX), for $2.9 billion in cash, bringing… Read more »

New Biogen pick for CEO inherits tough job; markets aren’t exactly enthralled–yet

Biogen Inc. (Cambridge MA) said Monday (December 19, 2016) it has named veteran biopharmaceutical executive Michel Vounatsos, head of the company’s commercial organization, its next chief executive. Mr. Vounatsos will succeed George Scangos, who announced earlier this… Read more »